A Phase 1 study of IBI363 in combination with Bevacizumab or Furuitinib in Subjects with Advanced Colorectal Cancer
Sign written informed consent and be able to comply with the program's visit schedule and related procedures.
Male or female subjects, age 18~75 years.
Histologically or cytologically confirmed advanced colorectal cancer.
Subjects who have progressed on standard therapy, who are unsuitable for standard therapy, who do not have standard therapy, or who have refused standard therapy.
Women who are pregnant or lactating, or intending to become pregnant before, during, or within 6 months after the last dose of study drug.
Active epileptic seizures or active central nervous system (CNS ) metastases and so on.
Clinically significant cardiovascular or cerebrovascular disease.
Interstitial pneumonia, pulmonary fibrosis, pneumoconiosis, drug-associated pneumonia, and radiation pneumonitis requiring steroid hormone or other therapy, as well as history of severe abnormal lung function or other forms of restrictive lung disease.